Share Us:

Resource Center for ADHD Prescription Medication

Intuniv Coupon

Lowest discount price for: Intuniv 2 MG TAB ER 24H at WINN DIXIE See More Pricing

Save 16% on Your Prescription

Average Retail:$353.47

Coupon Price:$295.86

Intuniv Prescription Drug Coupon

You can show the pharmacist this coupon from your phone.

Print this free Intuniv Coupon to get the lowest price on your prescription medication. This discount drug coupon is pre-activated and can be used immediately to save up to 75% at your pharmacy. This coupon is accepted at over 68,000 pharmacies nationwide, including: Walgreens, CVS Pharmacy, Walmart Pharmacy, Rite Aid, Kroger, Kmart Pharmacy, and Safeway.

Coupon Instructions

STEP 1: Print your coupon, it's pre-activated.

STEP 2: Bring to your local pharmacy.

STEP 3: Save on your prescription costs!

Intuniv 2 MG TAB ER 24H

Drug Information: Intuniv

Indications and Usage

INTUNIV® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

Dosing and Administration

Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of guanfacine release. Do not administer with high fat meals, due to increased exposure.

Take INTUNIV orally once daily, either in the morning or evening, at approximately the same time each day. Begin at a dose of 1 mg/day, and adjust in increments of no more than 1 mg/week.

In monotherapy clinical trials, there was dose- and exposure-related clinical improvement as well as risks for several clinically significant adverse reactions (hypotension, bradycardia, sedative events). To balance the exposure-related potential benefits and risks, the recommended target dose range depending on clinical response and tolerability for INTUNIV® is 0.05-0.12 mg/kg/day (total daily dose between 1-7 mg).

Dosage Forms and Strengths

  • 1 mg tablet
  • 2 mg tablet
  • 3 mg tablet
  • 4 mg tablet


INTUNIV is contraindicated in patients with a history of a hypersensitivity reaction to INTUNIV or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.

Warnings and Precautions

Treatment with INTUNIV® can cause dose-dependent decreases in blood pressure and heart rate. Decreases were less pronounced over time of treatment. Orthostatic hypotension and syncope have been reported.

Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate INTUNIV slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated. Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.

Somnolence and sedation were commonly reported adverse reactions in clinical studies. Before using INTUNIV® with other centrally active depressants, consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with INTUNIV®. Advise patients to avoid use with alcohol.

The sympatholytic action of INTUNIV® may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. Titrate INTUNIV slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.

Adverse Reactions

The following adverse reactions have been identified during post-approval use of guanfacine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Less frequent, possibly guanfacine-related events observed in the post-marketing study and/or reported spontaneously, not included in section 6.1, include:

  • General: edema, malaise, tremor
  • Cardiovascular: palpitations, tachycardia, rebound hypertension, hypertensive encephalopathy
  • Central Nervous System: paresthesias, vertigo
  • Eye Disorders: blurred vision
  • Musculo-Skeletal System: arthralgia, leg cramps, leg pain, myalgia
  • Psychiatric: confusion, hallucinations
  • Reproductive System, Male: impotence
  • Respiratory System: dyspnea
  • Skin and Appendages: alopecia, dermatitis, exfoliative dermatitis, pruritus, rash
  • Special Senses: alterations in taste

Drug Interactions

Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole: Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase in exposure

Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz: Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure